Trial · NCT01588353
Adverse events27
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 27
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site pain | General disorders | AK160 0.58 mg Step 1-3 | 78 | 102 | |
| other | Injection site bruising | General disorders | AK160 0.58 mg Step 1-3 | 46 | 102 | |
| other | Injection site swelling | General disorders | AK160 0.58 mg Step 1-3 | 35 | 102 | |
| other | Contusion | Injury, poisoning and procedural complications | AK160 0.58 mg Step 1-3 | 30 | 102 | |
| other | Injection site laceration | General disorders | AK160 0.58 mg Step 1-3 | 16 | 102 | |
| other | Nasopharyngitis | Infections and infestations | AK160 0.58 mg Step 1-3 | 16 | 102 | |
| other | Injection site oedema | General disorders | AK160 0.58 mg Step 1-3 | 12 | 102 | |
| other | Injection site haematoma | General disorders | AK160 0.58 mg Step 1-3 | 11 | 102 | |
| other | Local swelling | General disorders | AK160 0.58 mg Step 1-3 | 9 | 102 | |
| other | Laceration | Injury, poisoning and procedural complications | AK160 0.58 mg Step 1-3 | 9 | 102 | |
| other | Lymphadenitis | Blood and lymphatic system disorders | AK160 0.58 mg Step 1-3 | 6 | 102 | |
| other | Injection site pruritus | General disorders | AK160 0.58 mg Step 1-3 | 6 | 102 | |
| other | Glucose urine present | Investigations | AK160 0.58 mg Step 1-3 | 6 | 102 | |
| other | Haemorrhage subcutaneous | Skin and subcutaneous tissue disorders | AK160 0.58 mg Step 1-3 | 6 | 102 | |
| serious | Cataract | Eye disorders | AK160 0.58 mg Step 1-3 | 3 | 102 | |
| serious | Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | AK160 0.58 mg Step 1-3 | 1 | 102 | |
| serious | Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | AK160 0.58 mg Step 1-3 | 1 | 102 | |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | AK160 0.58 mg Step 1-3 | 1 | 102 | |
| serious | Duodenal ulcer perforation | Gastrointestinal disorders | AK160 0.58 mg Step 1-3 | 1 | 102 | |
| serious | Intestinal obstruction | Gastrointestinal disorders | AK160 0.58 mg Step 1-3 | 1 | 102 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01588353/events